Lindsey Cilia, MD
Interventional Cardiology · Falls Church, VANPI 1013329903
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.6%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Abbott at 47.1% of the total. 2025 is the largest year on record at $38,311, more than ten times the $128 reported in 2020. Among interventional cardiology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $144.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$23K
- Boston Scientific$13K
- Abiomed$3K
- Asahi Intecc USA, Inc.$2K
- Heartflow, Inc.$1K
- Medtronic$1K
- plus $5K from 23 others
What the payments were for
- Consulting fees$21,73844%
- Speaking & faculty fees$10,37521%
- Travel & lodging$3,9358%
- Food & beverage$13,39127%
- Education$3951%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 100 | $23,483 |
| Boston Scientific | 95 | $13,448 |
| Abiomed | 15 | $2,793 |
| Asahi Intecc USA, Inc. | 53 | $2,442 |
| Heartflow, Inc. | 2 | $1,400 |
| Medtronic | 11 | $1,223 |
| Cardiovascular Systems Inc. | 16 | $1,080 |
| Teleflex LLC | 8 | $983 |
| Biotronik Inc. | 5 | $793 |
| Shockwave Medical, Inc | 5 | $529 |
| Terumo Medical Corporation | 4 | $441 |
| Chiesi USA, Inc. | 3 | $394 |
| Penumbra, Inc. | 1 | $134 |
| E.r. Squibb & Sons, L.L.C. | 5 | $82 |
| Seigla Medical, Inc. | 1 | $82 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $82 |
| Astellas Pharma US Inc | 1 | $80 |
| Novartis | 4 | $80 |
| AstraZeneca | 2 | $46 |
| Novo Nordisk | 2 | $41 |
| Amgen | 2 | $36 |
| Philips North America LLC | 1 | $28 |
| Scpharmaceuticals Inc. | 1 | $26 |
| Pfizer | 1 | $26 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Merck | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Reflow Medical Inc | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIS$19,239
- GENERAL VASCULAR ACCESS$9,525
- PRESSUREWIRE$1,707
- FFRct$1,400
- GENERAL - THERAPIES$938
- Diamondback Coronary$870
- Asahi Coronary Wires$651
- GUIDELINER$399
- KENGREAL$394
- GlideWire$351
- Heartrail$351
- METACROSS OTW$351
- OPTICROSS$348
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$293
- ASAHI PTCA Guide Wire$291
- PERIPHERAL VASCULAR$290
- TURNPIKE$289
- AVVIGO Guidance System$229
- Asahi Peripheral Vascular Wires$204
- SUPERCROSS$201
How this compares
$49,833 in reported general payments places this provider in the 90th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $62,042 |
| Repatha SureclickEvolocumab | 41 | $47,897 |
| XareltoRivaroxaban | 24 | $39,586 |
| Ranolazine ErRanolazine | 85 | $15,945 |
| NexletolBempedoic Acid | 13 | $12,717 |
| Ezetimibe | 142 | $6,436 |
| Rosuvastatin Calcium | 104 | $2,169 |
| Metoprolol Succinate | 138 | $1,950 |
| Atorvastatin Calcium | 162 | $1,830 |
| Amlodipine Besylate | 90 | $790 |
| ClopidogrelClopidogrel Bisulfate | 48 | $761 |
| Valsartan | 11 | $735 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 53 | $670 |
| Losartan Potassium | 32 | $598 |
| Pravastatin Sodium | 25 | $595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $62,04246 claims |
| Esperion Therapeutics, Inc.Nexletol | $14 | $12,71713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Falls Church
- Noah JonesFalls Church$238K
- Wayne BatchelorFalls Church$196K
- Matthew SherwoodFalls Church$193K
- Nadim GelooFalls Church$41K
- Hazim El-HaddadFalls Church$39K
- Deepak TalrejaVirginia Beach$1.5M
- Rajiv TayalFredericksburg$984K
- Gansevoort DunningtonRichmond$440K
- Matthew SummersNorfolk$308K
- Michael GenVirginia Beach$207K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.